Antisense Oligonucleotide Service
In the increasingly competitive field of antisense oligonucleotide (ASO) drug development, selecting a partner
with strong technical foundations, comprehensive platform capabilities, and extensive project experience is
essential for accelerating the progression from concept to clinic and minimizing development risks. Since its
establishment, Creative Biogene has been dedicated to nucleic-acid–based technologies as its core focus. From
fundamental DNA primer synthesis to complex functional RNA preparation and, more recently, small-nucleic-acid drug
development, we have accumulated unparalleled technical expertise and practical know-how. Our team comprises
senior scientists with deep backgrounds in chemistry, biology, bioinformatics, and pharmaceutical science, all of
whom combine rigorous theoretical knowledge with exceptional problem-solving capabilities in real-world R&D
scenarios.
Background
Antisense oligonucleotides are short, chemically synthesized DNA or RNA molecules, typically 15–30 nucleotides in
length. ASOs bind precisely to their target mRNA via canonical Watson–Crick base pairing, thereby enabling
targeted modulation of gene expression.
ASO Mechanisms of Action
Figure 1. Common ASOs
Mechanisms of Action. (Schoch KM, et al., 2017)
RNase H1-mediated mRNA degradation
Once an ASO hybridizes with its target mRNA, a DNA–RNA heteroduplex is formed, which recruits cellular RNase H1.
This enzyme selectively cleaves the RNA strand, leading to mRNA degradation and subsequent inhibition of protein
synthesis.
Steric blocking
By binding to key functional regions on the mRNA—such as splice junctions, the 5' cap-proximal region, or
ribosome-binding sites—ASOs can physically interfere with splicing, translation initiation, or other regulatory
processes.
miRNA mimicry or inhibition
Specially engineered ASOs can mimic endogenous microRNAs or inhibit their functions, allowing them to participate
in intricate regulatory networks.
With their high specificity and programmability, ASO technologies have demonstrated remarkable therapeutic
potential across various conditions, including oncology, neurodegenerative disorders, inherited diseases,
metabolic disorders, and numerous rare diseases. Several ASO therapeutics—including nusinersen and inotersen—have
already gained FDA approval, marking the successful translation of this technology from bench to bedside.
Creative Biogene's Integrated ASO Service Solution
We recognize that each stage of drug development imposes distinct requirements for material quality. Accordingly,
we have established a complete production and quality-control system spanning research-grade to cGMP-grade
manufacturing. Whether you are in early target-discovery research, preclinical development, or progressing into
clinical trials, Creative Biogene can supply high-quality ASO materials tailored to your needs—ensuring data
reliability, regulatory compliance, and seamless project continuity.
Our Core Service Modules
A Four-Pillar Integrated Support System for ASO R&D
Our strengths stem not from a single capability, but from a synergistic ecosystem of complementary platforms.
01 Oligonucleotide Chemistry and Manufacturing Platform
A cornerstone of our technical portfolio, this platform provides:
- Scalability and Flexibility: Production ranging from nmol-scale for discovery research to kg-scale for
commercial needs.
- Advanced Modification and Conjugation Technologies: Expertise in over 200 chemical modifications—including
phosphorothioates, 2'-O-Me, 2'-MOE, LNA, and more—and precise conjugation with GalNAc, cholesterol, peptides,
antibodies, and other ligands to enhance PK and targeting profiles.
- Stringent Quality Standards: ASO purity consistently ≥90%, supported by advanced synthesis and purification
technologies such as RP-HPLC and IE-HPLC, ensuring superior batch-to-batch reproducibility.
02 Bioinformatics
In the era of data-driven drug discovery, we have built a next-generation intelligent ASO design system.
- Beyond Rule-Based Design: Our platform integrates extensive internal experimental datasets with public
databases, applying machine learning and deep learning algorithms to predict silencing potency, molecular
stability, and potential off-target effects with high accuracy.
- Rational Design for Higher Efficiency: This dramatically increases the success rate of lead identification and
shortens optimization cycles. Validated ASOs designed using our platform have achieved silencing efficiencies as
high as 98%.
03 Proprietary Chemical-Modification Strategies
Chemical modifications play a decisive role in determining drug-like properties. Based on comprehensive
bioinformatic and experimental evidence, we have developed multiple proprietary modification suites (e.g.,
GS1–GS7), each optimized for specific objectives such as enhanced stability, reduced off-target activity, or
maximal potency.
04 Rigorous Analytical and Quality Control Systems
Quality begins at the design stage and is ensured through uncompromising analytical rigor.
- Comprehensive Analytical Capabilities: Mass spectrometry, HPLC, UV spectrophotometry, sterility testing,
endotoxin assessment, and more—supporting full characterization of molecular identity, purity, potency, and
safety.
- Data Integrity and Traceability: All production and QC data meet regulatory requirements for completeness and
traceability, supporting smooth regulatory submissions.
Client Case Studies & Research Outcomes
Case Study 1
Expression of miR-206 in HCC cells, and human and murine HCC hepatic tissue
Paper
2019
Acta Biochimica et Biophysica Sinica |
DOI
Background
This study investigates microRNA-206 (miR-206) in hepatocellular carcinoma (HCC). miR-206 was
downregulated
in human HCC tissues, mouse HCC tumors, and HCC cell lines, while cMET was upregulated and inversely
correlated. Overexpression of miR-206 reduced HCC cell viability, colony formation, migration, and
invasion,
and increased apoptosis. Luciferase assays identified cMET as a direct miR-206 target via its 3′-UTR.
Restoring cMET reversed miR-206-mediated inhibition, and miR-206 suppressed xenograft tumor growth in
mice.
The findings suggest miR-206 acts as a tumor suppressor in HCC by targeting cMET.
Key Findings
miR-206 expression was significantly reduced in 27 human HCC tissues, a mouse HCC model, and HepG2,
SMMC-7721, and Huh7 cells compared with normal liver. Conversely, cMET was upregulated and negatively
correlated with miR-206. miR-206 overexpression inhibited cell viability, DNA synthesis, colony formation,
migration, and invasion, and promoted apoptosis, with increased caspase-3/7 activity and Bax, decreased
Bcl-2. Dual-luciferase reporter assays confirmed direct binding to the cMET 3′-UTR, reducing cMET mRNA and
protein. Restoring cMET reversed miR-206-induced inhibition of growth, migration, and apoptosis. In vivo,
miR-206-expressing HepG2 xenografts grew more slowly and weighed less than controls, supporting miR-206 as
a
tumor suppressor targeting cMET in HCC.
Contribution
Creative Biogene provided the miR-206 mimic, negative control mimic, miR-206 antisense oligonucleotide
(ASO), and negative control ASO used for all transfections. These reagents enabled the gain- and
loss-of-function experiments that established miR-206-mediated inhibition of HCC proliferation, migration,
invasion, apoptosis, and cMET targeting.
Case Study 2
The researchers conducted a preclinical evaluation of antagomiR-218 in myotonic dystrophy type 1 (DM1) using
the
HSALR mouse model and patient-derived myotubes. They quantified antagomiR-218 levels at 40–60 pM two weeks after
injection in HSALR mice and documented dose- and time-dependent molecular and functional responses, along with a
favorable toxicity profile after a single subcutaneous administration. In muscle tissue, they observed
restoration
of normal Mbnl1 subcellular distribution without changes in the proportion of myonuclei containing CUG foci. At
the same time, in patient-derived cells, antagomiR-218 improved fusion and differentiation and reversed up to
34%
of transcriptomic alterations. For these experiments, the researchers used antagomiR-218 and agomiR-218,
synthesized by Creative Biogene, incorporating 2′-O-methyl modifications (m), phosphorothioate linkages (∗), and
cholesterol conjugation (chol).
Figure 1. Target expression patterns across antagomiR-218 doses,
including reporter responses in C2C12 cells and the in vivo dose-response study design. (Cerro-Herreros
E, et al., 2021)
Case Study 3
The researchers induced colitis in male C57BL/6 mice with 3% DSS and administered antagomiR-200c or a
nonspecific
control, synthesized by Creative Biogene, by daily oral gavage starting two days before DSS treatment. They
found
that MIR200C-3p was upregulated by IL1B in Caco-2 cells and mouse enterocytes, and that antagomiR-200c prevented
IL1B- and DSS-induced decreases in occludin mRNA and protein, reducing tight junction permeability. Patient
colon
tissues and organoids from ulcerative colitis cases showed elevated IL1B and MIR200C-3p, and three-dimensional
modeling identified interacting sites in the occludin 3′UTR.
Figure 2. The effects of DSS-induced colitis and antagomiR-200c on
IL-1β, miR-200c-3p, occludin expression, intestinal permeability, body weight, and colon histology in
mice.(Rawat
M, et al., 2020)
Delivering Real Value to Your ASO Program
By integrating these four major platforms, Creative Biogene offers unmatched benefits:
A Seamless, End-to-End Solution
From sequence design and chemical modification to in vitro screening and in vivo
validation, we deliver a fully connected workflow without the risks associated with multi-vendor
transitions.
Enhanced Efficiency and Higher Success Rates
The combination of AI-assisted design with proprietary modification systems enables rapid
identification of potent, stable, and low-off-target candidates at reduced cost.
Effective Risk Control
A unified production pipeline spanning RUO to GMP ensures quality consistency and regulatory compliance
throughout development, reducing delays and failure risks stemming from material variability.
Contact Us
Creative Biogene is more than a service vendor—we are your trusted partner in therapeutic innovation. With
advanced technologies, industry-leading expertise, and a commitment to scientific excellence, we provide
high-value, high-quality ASO services designed to ensure your success.
If you have specific requirements or would like to discuss your project in greater detail, please feel free to
contact us. We look forward to collaborating with you to bring the next breakthrough in gene therapy to life.